Amplion, a Bend, Oregon-based biomarker intelligence company, closed its Series A financing round of undisclosed amount.
The round was led by Greycroft with participation from existing investors, including Revolution’s Rise of the Rest Seed Fund and Imagen Capital Partners.
The funds will allow the company to expand its sales and marketing efforts as well as accelerate product development.
Led by Chris Capdevila, CEO, Amanda Enstrom, PhD, Chief Product Officer, and Mike Harrington, Chief Technology Officer, Amplion provides an intelligence platform using machine learning and biomedical domain expertise to accelerate Precision Medicine. By harnessing biomedical evidence, the company’s solutions deliver actionable insights to enable strategic decisions in drug and diagnostic development.
Amplion has established partnerships with pharmaceutical and diagnostic companies that leverage the platform to discover new opportunities and realize strategic objectives.